Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bioavailability of Lynestrenol

K Shrimanker, J Akpoviroro, K Fotherby

    Arzneimittel-Forschung
    |January 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Gastroparesis with multiple sclerosis.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2006
    Same author

    What are children's trusts? Early findings from a national survey.

    Child: care, health and development·2006
    Same author

    A survey of the UK maxillofacial laboratory service: profiles of staff and work.

    The British journal of oral & maxillofacial surgery·2005
    Same author

    Does donor cardiopulmonary resuscitation time affect outcome in uncontrolled non-heart-beating donor renal transplants?

    Transplantation proceedings·2005
    Same author

    Old world cutaneous leishmaniasis infection in children: a case series.

    Archives of disease in childhood·2005
    Same author

    Response to Emerson et al. (Journal of Intellectual Disability Research, 48, 201-202).

    Journal of intellectual disability research : JIDR·2005

    Capsules significantly improved the bioavailability of lynestrenol and ethynyloestradiol compared to tablets. The capsule formulation ensured complete conversion of lynestrenol to norethisterone, enhancing drug efficacy.

    Area of Science:

    • Pharmacokinetics
    • Drug delivery systems
    • Hormone therapy

    Background:

    • Lynestrenol and ethynyloestradiol are commonly used in hormone therapy.
    • Optimizing drug bioavailability is crucial for therapeutic effectiveness.
    • Formulation differences can significantly impact drug absorption and metabolism.

    Purpose of the Study:

    • To compare the bioavailability of lynestrenol and ethynyloestradiol from capsule versus tablet formulations.
    • To assess the in vivo conversion of lynestrenol to its active metabolite, norethisterone, based on formulation.

    Main Methods:

    • Administering lynestrenol and ethynyloestradiol via capsule and tablet formulations to subjects.
    • Measuring plasma drug concentrations over time.
    • Calculating the area under the plasma concentration-time curve (AUC) to determine bioavailability.
    Keywords:
    BiologyClinical ResearchContraceptionContraceptive Agents, Estrogen--administraction and dosageContraceptive Agents, Female--administraction and dosageContraceptive Agents, Progestin--administraction and dosageContraceptive Agents--administraction and dosageDeveloped CountriesEnglandEthinyl Estradiol--administraction and dosageEuropeFamily PlanningHematological EffectsHemic SystemHuman VolunteersLynestrenol--administraction and dosageMenMetabolic EffectsNorthern EuropeOral ContraceptivesOral Contraceptives, CombinedPhysiologyResearch MethodologySteroid Metabolic EffectsUnited Kingdom

    Related Experiment Videos

  • Analyzing the conversion of lynestrenol to norethisterone.

    • Main Results:

    • The capsule formulation demonstrated superior bioavailability for both lynestrenol and ethynyloestradiol compared to the tablet formulation.
    • Area under the plasma concentration curves indicated enhanced absorption with the capsule.
    • Complete conversion of administered lynestrenol to norethisterone was observed with the capsule formulation.

    Conclusions:

    • Capsule formulations offer improved bioavailability for lynestrenol and ethynyloestradiol.
    • The enhanced bioavailability from capsules may lead to improved therapeutic outcomes.
    • The study highlights the importance of drug formulation in achieving optimal pharmacokinetic profiles.